Checkpoint Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
Biologics license application (“BLA”) for both metastatic and locally advanced cutaneous squamous cell carcinoma indications expected to be submitted by January 2023 WALTHAM, Mass., Nov. 08, 2022 ...
Checkpoint (2022), also known as “As Though Nothing Happened,” portrays the collective trauma of Damascus through the experiences of its people across seven years, highlighting the enduring ...
WALTHAM, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (CKPT) (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the ...
WALTHAM, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results